Diazepam Dosing for Alcohol Withdrawal
For most adults with alcohol withdrawal, start diazepam 10 mg orally or IV, then give 5–10 mg every 6–8 hours based on symptom severity (CIWA-Ar scores), tapering gradually after day 4; however, switch to lorazepam 2–4 mg every 4–6 hours in patients with cirrhosis or severe hepatic impairment to avoid dangerous drug accumulation. 1, 2, 3
Immediate Assessment and Thiamine Administration
Administer thiamine 100–500 mg IV immediately before any glucose-containing fluids to prevent precipitating acute Wernicke encephalopathy; this is mandatory for every patient. 1, 4, 2
Continue thiamine 100–300 mg/day orally throughout withdrawal and for 2–3 months after resolution. 1, 2
Assess vital signs for autonomic instability (tachycardia, hypertension, fever, sweating) and screen for dangerous complications: dehydration, electrolyte imbalance (especially magnesium), infection, gastrointestinal bleeding, pancreatitis, and hepatic encephalopathy. 1
Risk Stratification Using CIWA-Ar
CIWA-Ar 8–15 (uncomplicated moderate withdrawal): Initiate benzodiazepine therapy with symptom-triggered or fixed-schedule dosing. 1
CIWA-Ar ≥15 (severe withdrawal): Requires aggressive treatment with higher initial doses and close monitoring; carbamazepine monotherapy is absolutely contraindicated at this severity. 1, 4
Diazepam Dosing Protocol
Standard Dosing (No Hepatic Impairment)
Initial dose: 10 mg orally or IV, then 5–10 mg every 6–8 hours as needed based on CIWA-Ar scores and vital signs. 1, 2
Rationale: Diazepam has the shortest time-to-peak effect (5 minutes IV, 120 minutes oral), allowing rapid symptom control and accurate titration to avoid oversedation even in the first 24 hours. 3, 5
Long-acting benzodiazepines like diazepam provide superior protection against seizures and delirium tremens compared to shorter-acting agents due to self-tapering pharmacokinetics that produce smoother withdrawal with fewer breakthrough symptoms. 1, 4, 2, 5
Tapering Schedule
Begin tapering after approximately 96 hours (day 4) when acute symptoms are improving. 1
Reduce the daily dose by roughly 25% every 2–3 days, monitoring for rebound anxiety, tremor, or autonomic instability at each reduction. 1
Total benzodiazepine duration must not exceed 10–14 days to avoid iatrogenic dependence; complete discontinuation by day 14. 1, 2
Critical Exception: Hepatic Impairment
When to Switch to Lorazepam
Switch to lorazepam in patients with:
- Cirrhosis or severe hepatic impairment 1, 2, 3
- Elderly or frail patients 1, 2
- Respiratory compromise (COPD, sleep apnea) 1, 2
- Obesity 1, 2
- Recent head trauma 2
Why Diazepam Is Dangerous in Liver Disease
In hepatic insufficiency, chlordiazepoxide (and to a lesser extent diazepam) undergoes delayed metabolism, creating a reservoir of unmetabolized drug ("dose-stacking") that slowly converts to active metabolites with very long half-lives (demoxepam 14–95 hours), resulting in delayed, profound, and prolonged sedation that can occur even after dosing is stopped. 3
Recent 2025 evidence challenges the traditional avoidance of diazepam in liver disease: Diazepam's rapid time-to-peak effect remains unaffected by hepatic insufficiency, allowing accurate titration before each dose if the dosing interval exceeds the time-to-peak and sedation is assessed before each administration. 3
However, guideline consensus still recommends lorazepam as safer because it has no active metabolites and shorter half-life, minimizing accumulation risk. 1, 2
Lorazepam Dosing in Hepatic Impairment
Start lorazepam 2–4 mg orally, IV, or IM every 4–6 hours (total 6–12 mg/day), then taper. 1, 2
In elderly or frail patients, start at 0.25–1 mg (commonly 0.5 mg) every 4–6 hours and titrate cautiously. 1
Special Populations and Comparative Evidence
Cirrhotic Patients
Over 70% of cirrhotic patients may not require benzodiazepines at all when symptom-triggered dosing is used; treat only when CIWA-Ar ≥8. 1
When treatment is needed, lorazepam or oxazepam are preferred due to shorter half-lives and lack of active metabolites. 1, 2
Comparative Efficacy: Diazepam vs. Lorazepam
A 2024 ICU study found diazepam and lorazepam equally efficacious for severe AWS, with similar time to CIWA-Ar goal (12 vs. 14 hours, p=0.06) and similar 24-hour benzodiazepine requirements (p=0.05). 6
However, diazepam cost was 25-fold higher ($204.60 vs. $8.00, p<0.01), making lorazepam preferred when both are equally effective. 6
A 2009 study in uncomplicated withdrawal found lorazepam 8 mg/day and chlordiazepoxide 80 mg/day equally effective in reducing CIWA-Ar scores, with no difference in adverse events. 7
A 2015 study confirmed lorazepam is noninferior to chlordiazepoxide in reducing withdrawal symptoms (both groups showed significant CIWA-Ar reduction, p<0.0001). 8
Essential Supportive Care
Aggressive fluid and electrolyte replacement with magnesium supplementation is essential because magnesium is commonly depleted in chronic alcohol use. 1, 2
Continuous vital-sign monitoring to detect autonomic instability and complications. 1
Management of Severe or Refractory Withdrawal
Adjunctive Antipsychotics (ICU Setting Only)
- Haloperidol 0.5–5 mg may be added only as adjunctive therapy to adequate benzodiazepine dosing for severe agitation or hallucinations not controlled by benzodiazepines; never use as monotherapy because antipsychotics lower seizure threshold. 1
Second-Line Agents for Benzodiazepine-Refractory Cases
Phenobarbital or propofol can be used as second-line sedatives in ICU patients with severe AWS inadequately controlled by benzodiazepines. 1
Dexmedetomidine serves as adjunctive therapy only in severe, benzodiazepine-refractory ICU cases; it does not prevent seizures or delirium tremens and must not be used as monotherapy. 1
Medications to Avoid
Do not use anticonvulsants (phenytoin, carbamazepine) for alcohol-withdrawal seizures; benzodiazepines are the only proven therapy that prevents seizures and reduces mortality from delirium tremens. 1, 4
Never use antipsychotics as monotherapy; they increase seizure risk and worsen outcomes. 1
Avoid beta-blockers as sole treatment; they control tachycardia but do not prevent seizures or delirium tremens. 1
Post-Acute Management and Relapse Prevention
Mandatory psychiatric consultation after stabilization for evaluation of alcohol-use disorder severity and long-term abstinence planning. 1, 2
Evidence-based relapse-prevention medications after withdrawal completion:
- Acamprosate (~2 g/day for patients ≥60 kg) – safe in liver disease, reduces craving 1
- Baclofen (up to 80 mg/day) – the only medication with proven safety in cirrhotic patients 1
- Naltrexone – contraindicated in alcoholic liver disease due to hepatotoxicity risk 1
- Disulfiram – avoid in severe liver disease 1
- Topiramate – emerging evidence for relapse prevention 1
Encourage engagement with Alcoholics Anonymous or similar mutual-help groups. 1
Critical Pitfalls to Avoid
Never give glucose-containing IV fluids before thiamine; this can precipitate acute Wernicke encephalopathy. 1, 4, 2
Never extend benzodiazepine therapy beyond 14 days or discontinue abruptly; always taper gradually. 1, 2
Do not use chlordiazepoxide in hepatic impairment; significant risk of dose-stacking and prolonged sedation. 1, 3
Never rely on anticonvulsants or antipsychotics alone; benzodiazepines are mandatory for seizure prevention and mortality reduction. 1
Dispense benzodiazepines in limited quantities or supervise each dose to minimize misuse risk. 1